tiprankstipranks
Trending News
More News >

Neuren Pharmaceuticals Updates on Share Buy-Back Program

Story Highlights
Neuren Pharmaceuticals Updates on Share Buy-Back Program

Confident Investing Starts Here:

Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an update.

Neuren Pharmaceuticals Limited has announced an update on its ongoing share buy-back program, reporting the acquisition of 30,029 ordinary fully paid securities on the previous day. This buy-back initiative is part of the company’s strategy to enhance shareholder value and optimize its capital structure, reflecting a proactive approach to managing its financial resources.

The most recent analyst rating on (AU:NEU) stock is a Buy with a A$27.40 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development and commercialization of therapies for neurological disorders. The company is known for its work on treatments for conditions such as Rett syndrome and Fragile X syndrome, targeting significant unmet medical needs in the market.

Average Trading Volume: 745,726

Technical Sentiment Signal: Buy

Current Market Cap: A$1.73B

For detailed information about NEU stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App